EP1565200A4 - NUKLEINSûURE ENTSPRECHENDES PROTEIN 24P4C12 ZUR BEHANDLUNG UND ERKENNUNG VON KREBS - Google Patents

NUKLEINSûURE ENTSPRECHENDES PROTEIN 24P4C12 ZUR BEHANDLUNG UND ERKENNUNG VON KREBS

Info

Publication number
EP1565200A4
EP1565200A4 EP02789937A EP02789937A EP1565200A4 EP 1565200 A4 EP1565200 A4 EP 1565200A4 EP 02789937 A EP02789937 A EP 02789937A EP 02789937 A EP02789937 A EP 02789937A EP 1565200 A4 EP1565200 A4 EP 1565200A4
Authority
EP
European Patent Office
Prior art keywords
susse
nucleine
cancer
detection
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02789937A
Other languages
English (en)
French (fr)
Other versions
EP1565200A2 (de
Inventor
Arthur B Raitano
Karen Jane Meyrick Morrison
Wangmao Ge
Pia M Challita-Eid
Aya Jakobovits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of EP1565200A2 publication Critical patent/EP1565200A2/de
Publication of EP1565200A4 publication Critical patent/EP1565200A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP02789937A 2002-11-27 2002-11-27 NUKLEINSûURE ENTSPRECHENDES PROTEIN 24P4C12 ZUR BEHANDLUNG UND ERKENNUNG VON KREBS Withdrawn EP1565200A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/038264 WO2004050828A2 (en) 2002-11-27 2002-11-27 Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer

Publications (2)

Publication Number Publication Date
EP1565200A2 EP1565200A2 (de) 2005-08-24
EP1565200A4 true EP1565200A4 (de) 2009-06-24

Family

ID=32467113

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02789937A Withdrawn EP1565200A4 (de) 2002-11-27 2002-11-27 NUKLEINSûURE ENTSPRECHENDES PROTEIN 24P4C12 ZUR BEHANDLUNG UND ERKENNUNG VON KREBS

Country Status (6)

Country Link
EP (1) EP1565200A4 (de)
JP (1) JP2006508163A (de)
AU (3) AU2002352976B2 (de)
CA (1) CA2503346C (de)
IL (1) IL167892A (de)
WO (1) WO2004050828A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20130649T1 (hr) * 2007-09-07 2013-08-31 Agensys, Inc. Protutijela i povezane molekule koje se vežu za 24p4c12 proteine
EP2403524A4 (de) * 2009-03-06 2012-09-26 Agensys Inc An 24p4c12-proteine bindende antikörper-wirkstoffkonjugate (adc)
JP2013049646A (ja) * 2011-08-30 2013-03-14 Tokyo Medical Univ 癌治療剤
CA3000275A1 (en) * 2015-10-02 2017-04-06 University Of Copenhagen Small molecules blocking histone reader domains
US11513127B2 (en) 2016-01-25 2022-11-29 Genentech, Inc. Methods for assaying T-cell dependent bispecific antibodies
CN110799646B (zh) * 2017-04-28 2024-10-22 朋友股份有限公司 变态反应的抗原及其表位

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061746A1 (en) * 1999-04-12 2000-10-19 Agensys, Inc. 13 transmembrane protein expressed in prostate cancer
WO2001046258A2 (en) * 1999-12-23 2001-06-28 Incyte Genomics, Inc. Transporters and ion channels

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
EP0206448B1 (de) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU625013B2 (en) 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
JP3285355B2 (ja) 1992-06-04 2002-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｉｎｖｉｖｏ遺伝子治療のための方法及び組成物
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
ES2318848T3 (es) 1993-09-14 2009-05-01 Pharmexa Inc. Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria.
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
ATE511849T1 (de) 1996-03-11 2011-06-15 Epimmune Inc Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle
EP0960204A4 (de) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer Methoden und reagenzien zur genetischen immunisierung
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
JP2001512013A (ja) * 1997-08-01 2001-08-21 ジェンセット 前立腺に発現される分泌タンパク質の５’ｅｓｔ
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061746A1 (en) * 1999-04-12 2000-10-19 Agensys, Inc. 13 transmembrane protein expressed in prostate cancer
WO2001046258A2 (en) * 1999-12-23 2001-06-28 Incyte Genomics, Inc. Transporters and ion channels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004050828A2 *

Also Published As

Publication number Publication date
WO2004050828A2 (en) 2004-06-17
AU2002352976B2 (en) 2007-11-08
EP1565200A2 (de) 2005-08-24
AU2002352976A1 (en) 2004-06-23
CA2503346C (en) 2014-03-18
WO2004050828A3 (en) 2004-12-09
IL167892A (en) 2012-06-28
CA2503346A1 (en) 2004-06-17
JP2006508163A (ja) 2006-03-09
AU2009208065B2 (en) 2012-05-24
AU2009208065A1 (en) 2009-08-27
AU2008200628A1 (en) 2008-03-06
AU2008200628B2 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
ATE468331T1 (de) Neue cyanopyridine-derivate zur behandlung von krebs und anderer erkrankungen
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE60335293D1 (de) Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen
ATE551100T1 (de) Pharmazeutische zusammensetzung zur behandlung von kardiovaskulären und cerebrovasakulären erkrankungen
ATE542801T1 (de) Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
DE60224163D1 (de) Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE60313297D1 (de) Gerät zum nachweis und zur behandlung von synkope
EP1701664A4 (de) System und verfahren zur behandlung von gewebe
ATE494279T1 (de) Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
EP1626730A4 (de) Verfahren, gerät und zusammensetzung zur behandlung von akne
EA200500098A1 (ru) Лекарственное средство и способ лечения патологического синдрома
DE60030554T8 (de) Verwendungen von et743 zur behandlung von krebs
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
EP1487480A4 (de) Fusionsmoleküle und verfahren zur behandlung von immunkrankheiten
EP1694364A4 (de) System zur behandlung und prävention von brustkrebs
DE602004001134D1 (de) Tetrazolderivate und verfahren zur behandlung von stoffwechselbedingten erkrankungen damit
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60305400D1 (de) Anlage zur Behandlung von Produkten und dazugehörige Datenerfassungseinheit

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050421

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090525

17Q First examination report despatched

Effective date: 20090923

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AGENSYS, INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150304

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150715